Kraig Biocraft Laboratories Prepares for Challenge Testing of Disease Resistant Silkworm Lines
Immunity enhanced silkworms provide licensing opportunities into the broader $14 B1 silk industry
ANN ARBOR, Mich., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it is preparing to conduct challenge testing on two lines of immunity enhanced silkworms. These silkworm lines were developed by Kraig Labs to combat two of the biggest challenges facing the global silk production industry.
It has been reported that as much as 50% of all losses in silk production result from a single widespread virus. A 2020 paper cited that 75% of all interviewer silkworm raisers reported losses due to this disease. With no effective treatment, this virus results in countless millions of dollars of economic annually. Kraig Labs realized that technologies it was developing for other applications could be used to significantly reduce these losses in the broader silk industry. The Company has made rapid progress in the development of this new technology.
Specifically designed to target and combat this virus and other pathogens, these new transgenics developed by Kraig Labs, are now preparing to undergo challenge testing. These new disease-resistant lines of silkworms are intended for licensing into the global market for mundane silks to combat pathogenic viruses and fungi. The Company expects to make these lines of resilient silkworms available for commercial licensing shortly after the conclusion of successful challenge testing.
“We are very excited to begin challenge testing for these immunity enhanced silkworm lines,” said COO Jon Rice. “Our intention is to license this technology to silk produces all over the world. This program to produce licensable commercial lines of more robust silkworms is the perfect complement to our core focus, the commercialization of Kraig’s eco-friendly recombinant spider silk.”
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to .
___________________
1 From New Analysis from Global Industry Analysts Reveals Steady Growth for Silk, with the Market to Reach $21 Billion Worldwide by 2026, read more at:
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
